New drug combo targets tough cancers in early trial

NCT ID NCT04471727

Ongoing Disease control Sponsor: Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called HPN328, alone or with other medicines, in people with advanced small-cell lung cancer or neuroendocrine cancers that have a specific marker (DLL3). The main goals are to find the safest dose and understand side effects. About 232 adults will take part in this early-phase trial.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung neoplasm neuroendocrine carcinoma neuroendocrine neoplasm prostate cancer prostate neuroendocrine neoplasm small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEUROENDOCRINE; CARCINOMA SMALL CELL LUNG CANCER

Contacts and locations

Locations

Cedar-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute

Los Angeles, California, 90048, United States
Dana Farber Cancer Institute

Boston, Massachusetts, 02467, United States
Karmanos Cancer Center

Detroit, Michigan, 48201, United States
Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10021, United States
Providence

Portland, Oregon, 97213, United States
Roswell Park Comprehensive Cancer Center

Buffalo, New York, 14263, United States
Tennessee Oncology

Nashville, Tennessee, 37203, United States
University Hospitals Cleveland Medical Center

Cleveland, Ohio, 44106, United States
University of California San Francisco

San Francisco, California, 94143, United States
University of Colorado

Aurora, Colorado, 80045, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.